

**GOVERNMENT OF INDIA  
MINISTRY OF AYURVEDA, YOGA & NATUROPATHY,  
UNANI, SIDDHA AND HOMOEOPATHY  
(AYUSH)**

**RAJYA SABHA  
UNSTARRED QUESTION NO.3045  
TO BE ANSWERED ON 23<sup>rd</sup> March, 2021**

**AYURVEDIC DRUG FOR BREAST CANCER**

**3045 SHRI PARIMAL NATHWANI:**

Will the Minister of **AYURVEDA, YOGA AND NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY** be pleased to state:

- (a) whether Central Council for Research in Ayurvedic Sciences (CCRAS) in collaboration with AIIMS, New Delhi has conducted a clinical research study for evaluating quality of life with a coded Ayurvedic formulation named as ‘AYUSH QOL-2C’ in patients of local nonmetastatic breast cancer treated with adjuvant chemotherapy/radiotherapy and correlating it with Molecular Marker;
- (b) if so, the details of the clinical trials;
- (c) whether Government has given any approval for the manufacturing of this drug; and
- (d) if so, the details thereof?

**ANSWER  
THE MINISTER OF STATE (IC) OF THE MINISTRY OF YOUTH AFFAIRS AND  
SPORTS AND ADDITIONAL CHARGE OF MINISTER OF STATE (IC) OF THE  
MINISTRY OF AYURVEDA,  
YOGA & NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY  
(SHRI KIREN RIJU)**

- (a) Yes.
- (b): The Central Council for Research in Ayurvedic Sciences (CCRAS), which is an autonomous body under the aegis of Ministry of AYUSH, in collaboration with AIIMS, New Delhi, has conducted a prospective double blind randomized placebo controlled clinical trial entitled “*A Pilot Study Evaluating Quality of Life with AYUSH QOL – 2C in Patients of Local Non-Metastatic Breast Cancer Treated with Adjuvant Chemotherapy/Radiotherapy and Correlating it with Molecular Marker*” was conducted at AIIMS New Delhi, wherein 60 patients were enrolled. The Study revealed a trend towards better local control and survival in the Ayush “QOL 2 C” group and the drug was safe and well tolerated.

The research findings of the Study have been published as a Technical report “Ayurveda Intervention (Ayush QOL-2C)” in improving Quality of Life in Local Non Metastatic Breast Cancer as adjuvant to radiotherapy & Chemotherapy - A Report of Double Blind Randomized Placebo Controlled Clinical Study conducted in 2020, and the Research Paper has been submitted for publication in a reputed journal.

- (c) & (d): The Ayurvedic formulation - **Ayush QOL 2 C** - has been developed by CCRAS and patent has been filed for the same. The efforts are being made by CCRAS for technology transfer through National Research Development Corporation (NRDC) as per commercialization policy of CCRAS.